Trials / Completed
CompletedNCT05573698
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose and Multi-Dose Study of DT-216 in Adult Patients With Friedreich Ataxia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Design Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of multiple doses of intravenous DT-216 in adult patients with Friedrich Ataxia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DT-216 | DT-216 will be administered by intravenous (IV) injection |
| DRUG | Placebo | Matching Placebo will be administered by intravenous (IV) injection |
Timeline
- Start date
- 2022-09-27
- Primary completion
- 2023-08-25
- Completion
- 2023-08-25
- First posted
- 2022-10-10
- Last updated
- 2024-02-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05573698. Inclusion in this directory is not an endorsement.